MAM
ORKA

Marquette Asset Management’s Oruka Therapeutics ORKA Stock Holding History

Marquette Asset Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,443
Closed -$34.5K – 305
2023
Q1 		$34.5K Hold
1,443
– – 0.01% 157
2022
Q4 		$41K Hold
1,443
– – 0.01% 158
2022
Q3 		$36K Hold
1,443
– – 0.01% 154
2022
Q2 		$43K Hold
1,443
– – 0.01% 172
2022
Q1 		$40K Buy
+1,443
New +$35.8K 0.01% 200

Other funds holding ORKA

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marquette Asset Management's ORKA Position: Q2 2023 in Review

Marquette Asset Management sold out of Oruka Therapeutics (ORKA) in Q2 2023, closing a stake of 1,443 shares — an estimated $34.5K sold.

Marquette Asset Management first reported a position in ORKA in Q1 2022 and held it in 5 quarters. The position peaked at $43K in Q2 2022. 23 funds tracked by Wall St. Rank hold ORKA as of Q2 2023.

  • Marquette Asset Management reported no remaining Oruka Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Marquette Asset Management sold 1,443 Oruka Therapeutics shares in Q2 2023, an estimated $34.5K.
  • Marquette Asset Management first reported a position in Oruka Therapeutics in Q1 2022 and held it in 5 quarters.
  • Marquette Asset Management's Oruka Therapeutics position peaked at $43K in Q2 2022.
  • 23 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2023.

Based on Marquette Asset Management's 13F filing for Q2 2023, filed 28 Jul 2023.